Institution
Institute of Hematology & Blood Diseases Hospital
Also known as: Institute of Hematology and Blood Diseases Hospital · 中国医学科学院血液病医院
- 152running trials
- 37closed trials
- 7,003publications (OpenAlex)
Running trials
Not yet recruiting
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Not yet recruiting
Not yet recruiting
Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Not yet recruiting
Recruiting
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Enrolling by invitation
Not yet recruiting
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Not yet recruiting
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
Recruiting
Active, not recruiting
Recruiting
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
Recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
Recruiting
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Not yet recruiting
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Recruiting
Not yet recruiting
Recruiting
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Recruiting
Not yet recruiting
Enrolling by invitation
Recruiting
Recruiting
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Recruiting
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
Recruiting
Not yet recruiting
Not yet recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Recruiting
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Recruiting
Not yet recruiting
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Recruiting
Recruiting
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Recruiting
Showing 50 of 152.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Multiple myeloma28 recruiting
- Acute lymphoblastic leukaemia22 recruiting
- Acute myeloid leukaemia19 recruiting
- Childhood cancers16 recruiting
- Immune thrombocytopenia (ITP)11 recruiting
- Haemophilia9 recruiting
- Chronic lymphocytic leukaemia6 recruiting
- Myeloproliferative neoplasms6 recruiting
- Lupus (SLE)5 recruiting
- Myelodysplastic syndromes5 recruiting
- ANCA-associated vasculitis4 recruiting
- Aplastic anaemia4 recruiting
- Diffuse large B-cell lymphoma4 recruiting
- Follicular lymphoma4 recruiting
- Mantle cell lymphoma4 recruiting
- Systemic sclerosis (scleroderma)4 recruiting
- Antiphospholipid syndrome3 recruiting
- Dermatomyositis and polymyositis (myositis)2 recruiting
- ALS (motor neurone disease)1 recruiting
- Amyloidosis1 recruiting
- Chronic myeloid leukaemia1 recruiting
- Cytomegalovirus infection1 recruiting
- Rheumatoid arthritis1 recruiting
- Sjögren's disease1 recruiting
- Thalassaemia1 recruiting
Closed trials
Withdrawn
Withdrawn
Completed
Completed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Recruiting
Completed
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
Terminated
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Completed
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Withdrawn
Completed
Completed
Completed
Terminated
Completed
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
Terminated
Completed
Completed
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Completed
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
Completed
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Completed
Completed
Completed
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
Terminated
Completed
Terminated
Completed
Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA
Terminated
A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
Completed
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Registry name variants (39)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality 300020
68 trials
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, 300000
29 trials
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China 300041
20 trials
Institute of Hematology and Blood Diseases Hospital
Tianjin, 300320
8 trials
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, Tianjin Municipality 300020
7 trials
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, 300000
7 trials
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
Tianjin, Tianjin Municipality 301600
5 trials
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality 300020
4 trials
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
Tianjin, Tianjin Municipality 301617
4 trials
Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology
Tianjin, Tianjin Municipality 300020
4 trials
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality 301636
4 trials
Institute of Hematology & Blood Diseases Hospital
Tianjing
2 trials
Contact: Lu gui Qiu Doctor
Contact: Zimin Sun
Institute of Hematology and Blood Diseases Hospital
Beijing
1 trial
NCT06232096A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Contact: Lugui Qiu, Doctor
Institute of Hematology and Blood Diseases Hospital
Xiaobailou, Tianjin Municipality 300020
1 trial
NCT05101187Olorofim Aspergillus Infection Study
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Tianjin
1 trial
NCT06900088Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Contact: Erlie jiang
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology and Blood Diseases Hospital, Tianjin, China
Tianjin, 300020
1 trial
NCT07137637HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Contact: Mingyuan Sun, MD
Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Pek
Tianjin, 510080
1 trial
Institute of Hematology & Blood Diseases Hospital
Beijing
1 trial
Contact: Erlie Jiang, M.D.;Ph.D
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality 300020
1 trial
NCT06244368GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Contact: Wei Liu
Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai Sciences
Tianjin, Tianjin Municipality 300000
1 trial
Contact: Xiaofan Zhu, M.D
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology &Blood Diseases Hospital ,Chinese Academy of medical science & Peking Union Medical College
Tianjin
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, Tianjin Municipality
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences - Investigational Site Number: 15602
Tianjin, Tianjin Municipality 300020
1 trial
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio (Site 2800)
Tianjin, Tianjin Municipality 301617
1 trial
Contact: Study Coordinator
Institute of Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
Tianjin
1 trial
Contact: jianxiang Wang, MD
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin
1 trial
NCT07620275Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Contact: Lugui Qiu, M.D.
The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
Tianjin, Tianjin Municipality 300020
1 trial
Contact: Fengkui Zhang, Dr.
Conditions
Diseases this institution publishes on or runs trials for.
- Acute myeloid leukaemia65 works · 30 trials
- Acute lymphoblastic leukaemia47 works · 27 trials
- Multiple myeloma32 works · 40 trials
- Myeloproliferative neoplasms27 works · 9 trials
- Immune thrombocytopenia (ITP)21 works · 14 trials
- Haemophilia19 works · 20 trials
- Aplastic anaemia18 works · 5 trials
- Chronic lymphocytic leukaemia17 works · 10 trials
- Chronic myeloid leukaemia16 works · 1 trial
- Myelodysplastic syndromes14 works · 6 trials
- Diffuse large B-cell lymphoma10 works · 9 trials
- Mantle cell lymphoma5 works · 7 trials
Institution data: ROR 04n16t016 (CC0-1.0)Updated 15 Nov 2026